This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Spectrum Pharmaceuticals, Inc.
Drug Names(s): EO9, Apaziquone, EOquin
Description: Apaziquone is a novel bioreductive prodrug that is activated, to become a cytotoxic alkylating agent, by bio-reductive enzymes, such as DT-diaphorase, that are over-expressed in bladder cancer cells.
Revenue splits for this drug are BioMedTracker estimates.
Spectrum and INC Research
In 2001, Spectrum in-licensed exclusive worldwide rights to EOquin from INC Research in exchange for an up front fee, additional payments based upon achievement of certain milestones and a royalty based on net sales, if any, if and when a commercial drug is approved and sales are initiated. The term of the agreement expires when all patents that are the subject of the license in the agreement expire, although some obligations survive termination.
Allergan and Spectrum
In October 2008, Allergan and Spectrum Pharmaceuticals announced signing an exclusive collaboration for the development and commercialization of EOquin. Under the terms of the agreement, Allergan will pay Spectrum $41.5 million at closing and will make additional payments of up to $304 million based on the achievement of certain development, regulatory and commercialization milestones.
Spectrum...See full deal structure in Biomedtracker
Partners: INC Research Holdings, Inc. Allergan plc Nippon Kayaku Co., Ltd.
Additional information available to subscribers only: